Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 9/20 | 0.60 |
| ▸ | MMP3 | P08254 | 3/20 | 0.60 |
| ▸ | MMP1 | P03956 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | MMP7 | P09237 | 2/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | MMP8 | P22894 | 2/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | MMP14 | P50281 | 2/20 | 0.59 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.59 |
| ▸ | MMP15 | P51511 | 1/20 | 0.52 |
| ▸ | MMP16 | P51512 | 1/20 | 0.52 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7239280 | 1.00 | ADAM17 (0.60) | ADAM17MMP3MMP1MMP2MMP7 | |
| Trifluoroacetic Acid SCHEMBL7231444 | 0.99 | ADAM17 (0.60) | ADAM17MMP3MMP1MMP2MMP7 | |
| Trifluoroacetic Acid SCHEMBL7240079 | 0.99 | ADAM17 (0.60) | ADAM17MMP3MMP1MMP2MMP7 | |
| Trifluoroacetic Acid SCHEMBL7230906 | 0.99 | ADAM17 (0.60) | ADAM17MMP3MMP1MMP2MMP7 | |
| SCHEMBL7240588 | 0.96 | ADAM17 (0.65) | ADAM17MMP3MMP1MMP2MMP7 | |
| SCHEMBL7240596 | 0.96 | ADAM17 (0.65) | ADAM17MMP3MMP1MMP2MMP7 | |
| SCHEMBL7239432 | 0.96 | ADAM17 (0.65) | ADAM17MMP3MMP1MMP2MMP7 | |
| SCHEMBL7239421 | 0.96 | ADAM17 (0.65) | ADAM17MMP3MMP1MMP2MMP7 | |
| SCHEMBL7232659 | 0.94 | ADAM17 (0.65) | ADAM17MMP3MMP1MMP2MMP7 | |
| SCHEMBL7232652 | 0.94 | ADAM17 (0.65) | ADAM17MMP3MMP1MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-11 | — | — | US | claimed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042398-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | ADAM17 3/4885MMP3 11/4885MMP1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.